Zinc-MNP Trial for Prevention of Diarrhea and Promotion of Linear Growth

NCT03406793 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2886

Last updated 2020-11-03

No results posted yet for this study

Summary

This is a randomized, double-blind, community-based efficacy trial of different doses, forms, and frequencies of zinc supplementation for the prevention of diarrhea and promotion of linear growth among children 9-11 months of age in Dhaka, Bangladesh.

Conditions

Interventions

DIETARY_SUPPLEMENT

Standard MNP

Standard MNP, 15 micronutrients (Vitamin A 400 µg, vitamin D 5 µg, vitamin E 5 mg, vitamin C 30 mg, thiamine 0.5 mg, riboflavin 0.5 mg, niacin 6 mg, pyridoxine 0.5 mg, vitamin B12 0.9 mg, folate 150 µg, iron 10 mg, zinc 4.1 mg, copper 0.56 mg, selenium 17.0 µg and iodine 90 µg). Daily supplementation for 24 weeks.

DIETARY_SUPPLEMENT

High zinc, low iron MNP

Same as group 1, except with 10 mg zinc instead of 4.1 mg and 6 mg iron instead of 10 mg. Daily supplementation for 24 weeks.

DIETARY_SUPPLEMENT

High zinc, low/no iron on alternating days

Same as study group 1, except with 10 mg zinc instead of 4.1 mg, and 6 mg iron and no iron on alternating days instead of 10 mg. Daily supplementation for 24 weeks.

DIETARY_SUPPLEMENT

Dispersible zinc supplement

10 mg zinc in a dispersible tablet. Daily supplementation for 24 weeks.

DIETARY_SUPPLEMENT

Intermittent zinc supplement

10 mg zinc in a dispersible tablet. Daily supplementation for 14 days at baseline and 3 months, placebo tablet on all other days.

DIETARY_SUPPLEMENT

Placebo powder

Daily provision of a placebo powder for 24 weeks.

Sponsors & Collaborators

  • International Centre for Diarrhoeal Disease Research, Bangladesh

    collaborator OTHER
  • Johns Hopkins Bloomberg School of Public Health

    collaborator OTHER
  • University of Colorado, Denver

    collaborator OTHER
  • UCSF Benioff Children's Hospital Oakland

    lead OTHER

Principal Investigators

  • Robert Black, MD, MPH · Johns Hopkins Bloomberg School of Public Health

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
9 Months
Max Age
11 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-02-20
Primary Completion
2020-01-12
Completion
2020-01-12

Countries

  • Bangladesh

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03406793 on ClinicalTrials.gov